Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells $492,818.85 in Stock

Arcus Biosciences, Inc. (NYSE:RCUSGet Free Report) COO Jennifer Jarrett sold 24,555 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.07, for a total transaction of $492,818.85. Following the completion of the sale, the chief operating officer now owns 274,323 shares of the company’s stock, valued at approximately $5,505,662.61. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jennifer Jarrett also recently made the following trade(s):

  • On Friday, December 22nd, Jennifer Jarrett sold 21,521 shares of Arcus Biosciences stock. The stock was sold at an average price of $17.76, for a total value of $382,212.96.

Arcus Biosciences Trading Down 5.1 %

Shares of RCUS traded down $1.03 during midday trading on Wednesday, hitting $19.15. 749,181 shares of the company’s stock traded hands, compared to its average volume of 936,060. The firm’s fifty day moving average is $17.14 and its 200-day moving average is $17.28. Arcus Biosciences, Inc. has a 1 year low of $12.95 and a 1 year high of $25.47. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -4.61 and a beta of 0.78.

Arcus Biosciences (NYSE:RCUSGet Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The business had revenue of $31.00 million for the quarter, compared to analyst estimates of $28.30 million. During the same quarter in the prior year, the business posted ($0.93) EPS. Arcus Biosciences’s revenue for the quarter was down 8.8% compared to the same quarter last year. On average, equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.16 EPS for the current year.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RCUS. Citigroup Inc. lifted its holdings in shares of Arcus Biosciences by 20.8% during the third quarter. Citigroup Inc. now owns 145,729 shares of the company’s stock worth $2,616,000 after purchasing an additional 25,083 shares during the period. Barclays PLC boosted its holdings in Arcus Biosciences by 183.4% in the 3rd quarter. Barclays PLC now owns 470,776 shares of the company’s stock worth $8,451,000 after buying an additional 304,683 shares during the last quarter. Dark Forest Capital Management LP purchased a new position in shares of Arcus Biosciences in the third quarter valued at approximately $686,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Arcus Biosciences by 20.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,732 shares of the company’s stock worth $246,000 after buying an additional 2,289 shares in the last quarter. Finally, FMR LLC grew its stake in Arcus Biosciences by 4.9% during the 3rd quarter. FMR LLC now owns 4,780,052 shares of the company’s stock valued at $85,802,000 after acquiring an additional 222,280 shares in the last quarter. Hedge funds and other institutional investors own 74.67% of the company’s stock.

Analyst Ratings Changes

RCUS has been the topic of a number of research reports. Morgan Stanley reduced their target price on shares of Arcus Biosciences from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Monday, November 13th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Arcus Biosciences in a research note on Thursday, February 22nd. Mizuho cut their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, January 30th. Finally, Cantor Fitzgerald lowered their price target on shares of Arcus Biosciences from $46.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $41.25.

Read Our Latest Research Report on RCUS

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Read More

Insider Buying and Selling by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.